Compare Fabrinet (FN) vs Hims and Hers Health Inc (HIMS) Price & Performance

Fabrinet (FN) trades at $497.99, up 1.81% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 45% year-over-year revenue growth in Q4 2026 and consistent earnings beats, driven by surging AI data center demand. Valuation ratios like P/E of 37.34 and P/S of 3.81 reflect high growth expectations. Recent news highlights capacity expansion and AI-driven growth, though high RSI levels suggest potential overbought conditions.

The outlook for FN is positive, with a consensus price target of $769.50 implying significant upside. Key opportunities include AI infrastructure demand and operational leverage, but risks involve customer concentration, margin pressure from high spending, and insider selling. Investors should weigh strong growth prospects against valuation and execution risks in a competitive sector.

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.